Kelli Greene

TL;DR: There is an urgent need to establish standard panels of HIV-1 reference strains for wide distribution and a lack of uniformity in target strains used by different investigators to assess cross-neutralization has made the comparison of vaccine-induced antibody responses difficult.

TL;DR: The formal optimization and validation of the TZM-bl assay was performed in compliance with Good Clinical Laboratory Practice (GCLP) guidelines and the assay was evaluated for specificity, accuracy, precision, limits of detection and quantitation, linearity, range and robustness.

TL;DR: Key genetic and antigenic properties of subtype C HIV-1 that might impact the design and testing of candidate vaccines are illustrated.

TL;DR: The results suggest either that weak neutralizing antibody responses can be partially protective against HIV-1 in low-risk heterosexual populations or that the modest efficacy seen in RV144 was mediated by other immune responses, either alone or in combination with neutralizing antibodies.

TL;DR: A global panel of reference Env clones from among 219 Env-pseudotyped viruses assayed in TZM-bl cells with sera from 205 HIV-1-infected individuals was identified and was highly sensitive for detection of many of the known broadly neutralizing antibodies.